DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: NOVANTRONE (mitoxantrone)
       *****************************************************
       #Post#: 586--------------------------------------------------
       (Abst.) Lack of efficacy of mitoxantrone in PPMS
       By: agate Date: December 12, 2014, 3:20 pm
       ---------------------------------------------------------
       I can't determine how "peer-reviewed" the Journal of
       Neuroimmunology is but this abstract concerns mitoxantrone, and
       there hasn't been much about it lately.
       From PubMed, December 4, 2014:
       [quote]J Neuroimmunol. 2014 Nov 20. pii: S0165-5728(14)00978-3.
       doi: 10.1016/j.jneuroim.2014.11.017.
       Lack of efficacy of mitoxantrone in primary progressive multiple
       sclerosis irrespective of pharmacogenetic factors: A
       multi-center, retrospective analysis
       Grey Née Cotte S1, Salmen Née Stroet A1, von Ahsen N2, Starck
       M3, Winkelmann A4, Zettl UK4, Comabella M5, Montalban X5, Zipp
       F6, Fleischer V6, Kruse N7, Gold R1, Chan A8.
       Author information
       1Department of Neurology, St. Josef-Hospital, Ruhr University,
       Bochum, Germany.
       2Department of Clinical Chemistry, Medical Faculty, University
       of Göttingen, Germany.
       3Marianne-Strauß-Klinik, Berg, Germany.
       4Department of Neurology, University of Rostock, Germany.
       5Department of Neurology-Neuroimmunology, Centre
       d'EsclerosiMúltiple de Catalunya (Cemcat), Institut de
       RecercaValld'Hebron (VHIR), Hospital UniversitariValld´Hebron,
       UniversitatAutònoma de Barcelona, Spain.
       6University Medicine Mainz, Johannes Gutenberg University Mainz,
       Department of Neurology, Germany.
       7Institute of Neuropathology, University Medical Center
       Göttingen, Germany.
       8Department of Neurology, St. Josef-Hospital, Ruhr University,
       Bochum, Germany. Electronic address: Andrew.Chan@rub.de.
       BACKGROUND:
       Mitoxantrone is used on an off-label basis in primary
       progressive MS (PPMS). ABC-transporter-genotypes are associated
       with therapeutic response in relapsing/secondary progressive MS
       (RP/SPMS).
       OBJECTIVE:
       To evaluate potential pharmacogenetic response markers for
       mitoxantrone in PPMS.
       METHODS:
       41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated
       RP/SPMS-patients and 43 PPMS-controls were retrospectively
       assessed for clinical therapy-response and in correlation with
       four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes.
       RESULTS:
       53.7% PPMS-patients were mitoxantrone-responders, in comparison
       to 78.1% of RP/SPMS-patients (p=0.039). There was no association
       between genotype and treatment response.
       CONCLUSION:
       Our data discourages the use of mitoxantrone in PPMS regardless
       of pharmacogenetic response markers previously described in
       RP/SPMS.
       PMID: 25468777[/quote]
       The abstract  can be seen here
  HTML http://www.ncbi.nlm.nih.gov/pubmed/25468777.
       *****************************************************